Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 1.00 |
| ▸ | FABP1 | P07148 | 1/20 | 0.53 |
| ▸ | FABP6 | P51161 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8264991 | 0.90 | BACE1 (0.82) | BACE1FABP1FABP6RPS6KB1HDAC1 | |
| SCHEMBL5215132 | 0.86 | BACE1 (0.78) | BACE1 | |
| SCHEMBL21427815 | 0.85 | BACE1 (0.73) | BACE1HDAC1APPKDM4EHPGD | |
| SCHEMBL11095805 | 0.85 | BACE1 (0.73) | BACE1RPS6KB1HDAC1APPKDM4E | |
| SCHEMBL14007511 | 0.83 | BACE1 (0.71) | BACE1LTA4HMAPK14SHMT2EGFR | |
| SCHEMBL14007501 | 0.82 | BACE1 (0.68) | BACE1LTA4HMAPK14KDM4E | |
| SCHEMBL8265024 | 0.81 | BACE1 (0.68) | BACE1 | |
| SCHEMBL5646100 | 0.81 | BACE1 (0.68) | BACE1RPS6KB1HDAC1EGFRAPP | |
| SCHEMBL396451 | 0.79 | BACE1 (0.65) | BACE1HSD17B10HDAC1APPKDM4E | |
| SCHEMBL29922357 | 0.79 | BACE1 (0.65) | BACE1HSD17B10HDAC1APPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| CN-118974035-A | 2-Aminoimidazole derivatives as PRMT5 inhibitors | 米拉蒂医疗股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4426690-A2 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023081367-A2 | 2-AMINO IMIDAZOLE DERIVATIVES | Mirati Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081367-A2 | 2-AMINO IMIDAZOLE DERIVATIVES | Mirati Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-9296748-B2 | Pyridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-9296748-B2 | Pyridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-20150246919-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INT (DE) | 2015-09-03 | — | — | US | disclosed |
| US-20150246919-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INT (DE) | 2015-09-03 | — | — | US | disclosed |
| WO-2015022332-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | WO | disclosed |
| US-20150051208-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051208-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| EP-0033094-B1 | IMIDAZO(1,2-A)PYRIDINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1984-10-10 | — | — | EP | disclosed |
| US-4450164-A | ANTIULCER AND ANTISECRETORY AGENTS | SCHERING CORPORATION (US) | 1984-05-22 | — | — | US | disclosed |
| US-4358454-A | ANTIULCER AGENT | SCHERING CORPORATION (US) | 1982-11-09 | — | — | US | disclosed |
| EP-0033094-A1 | Imidazo(1,2-a)pyridines, processes for their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1981-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | BACE1 3899/4885FABP1 3509/4885FABP6 4680/4885 |
| US-20150051208-A1 | PYRIDINONES | MKI67, XDH, CDK6 | BACE1 2651/4885FABP1 4303/4885FABP6 1126/4885 |
| US-20150246919-A1 | PYRIDINONES | MKI67, XDH, CDK6 | BACE1 2651/4885FABP1 4303/4885FABP6 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.